Malta - English - Medicines Authority

galenicum health, s.l.u calle sant gabriel, 50 esplugues de llobregat 08950 barcelona, spain - rosuvastatin - film-coated tablet - rosuvastatin 20 mg - lipid modifying agents

Malta - English - Medicines Authority

galenicum health, s.l.u calle sant gabriel, 50 esplugues de llobregat 08950 barcelona, spain - rosuvastatin - film-coated tablet - rosuvastatin 40 mg - lipid modifying agents

Malta - English - Medicines Authority

biofarm sp. zo.o walbrzyska str 13, 60-198, poznan, poland - rosuvastatin - film-coated tablet - rosuvastatin 5 mg - lipid modifying agents

Malta - English - Medicines Authority

biofarm sp. zo.o walbrzyska str 13, 60-198, poznan, poland - rosuvastatin - film-coated tablet - rosuvastatin 10 mg - lipid modifying agents

Malta - English - Medicines Authority

biofarm sp. zo.o walbrzyska str 13, 60-198, poznan, poland - rosuvastatin - film-coated tablet - rosuvastatin 20 mg - lipid modifying agents

Malta - English - Medicines Authority

medichem, s.a. fructuós gelabert 6-8, 08970, sant joan despí, (barcellona), spain - rivaroxaban - film-coated tablet - rivaroxaban 10 mg - antithrombotic agents

Malta - English - Medicines Authority

medichem, s.a. fructuós gelabert 6-8, 08970, sant joan despí, (barcellona), spain - rivaroxaban - film-coated tablet - rivaroxaban 15 mg - antithrombotic agents

Malta - English - Medicines Authority

medichem, s.a. fructuós gelabert 6-8, 08970, sant joan despí, (barcellona), spain - rivaroxaban - film-coated tablet - rivaroxaban 20 mg - antithrombotic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - tenofovir alafenamide, quantity: 10 mg; darunavir, quantity: 800 mg; cobicistat, quantity: 150 mg; emtricitabine, quantity: 200 mg - tablet, film coated - excipient ingredients: magnesium stearate; croscarmellose sodium; silicon dioxide; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - symtuza is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in adults and adolescents (aged 12 years and older with body weight at least 40 kg). genotypic testing should guide the use of symtuza (see section 4.2 dose and method of administration, section 4.4 special warnings and precautions for use and section 5.1 pharmacodynamic properties).

Malta - English - Medicines Authority

vocate pharmaceuticals s.a 150, gounari str, 166 74 glyfada, athens, greece - prasugrel - film-coated tablet - prasugrel 5 mg - antithrombotic agents